Cabaletta Bio Reports Progress in Clinical Trials

Cabaletta Bio, Inc. ( (CABA) ) has released its Q2 earnings. Here is a breakdown of the information Cabaletta Bio, Inc. presented to its investors.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing targeted cell therapies for autoimmune diseases, with its headquarters in Philadelphia, PA. In its recent earnings report, Cabaletta Bio highlighted significant progress in its clinical development programs, particularly with its lead investigational therapy, rese-cel, designed to treat autoimmune diseases. The company is on track to initiate enrollment for myositis registrational cohorts and plans to submit its first Biologics License Application (BLA) in 2027. Key financial metrics for the second quarter of 2025 include research and development expenses of $37.6 million and a net loss of $45.1 million. The company successfully closed a $100 million public offering, extending its cash runway into the second half of 2026. Looking forward, Cabaletta Bio aims to continue advancing its clinical trials and regulatory discussions, with expectations to present new clinical data and achieve further milestones in its development pipeline.